We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+42.53%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.08B
AUM Growth
+$924M
(+43%)
Cap. Flow
+$456M
Cap. Flow
% of AUM
14.8%
Top 10 Holdings %
Top 10 Hldgs %
38.34%
Holding
121
New
53
Increased
26
Reduced
7
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$122M |
| 2 |
Eli Lilly
LLY
|
+$121M |
| 3 |
Maravai LifeSciences
MRVI
|
+$96M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$78.7M |
| 5 |
Avantor
AVTR
|
+$51.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$104M |
| 2 |
Merck
MRK
|
+$94.9M |
| 3 |
Biogen
BIIB
|
+$81.3M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$67.1M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$52.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.07% |
| 2 | Technology | 1.87% |
| 3 | Financials | 0.18% |
| 4 | Industrials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Bausch Health
BHC
$1.69B
| $41M | 1.33% |
+1,972,000
| New | +$36.8M |
|
|
KDMN
27
DELISTED
Kadmon Holdings, Inc.
KDMN
| $39.7M | 1.29% |
9,570,000
+540,000
| +6% | +$2.13M |
|
|
XLRN
28
DELISTED
Acceleron Pharma
XLRN
| $38.3M | 1.24% |
+299,000
| New | +$35.1M |
|
29
Sarepta Therapeutics
SRPT
$1.63B
| $37.1M | 1.2% |
+217,400
| New | +$32.2M |
|
|
LONA
30
LeonaBio Inc
LONA
$65.5M
| $35.8M | 1.16% |
104,387
+1,753
| +2% | +$414K |
|
31
Medtronic
MDT
$111B
| $35.3M | 1.14% |
301,000
+120,000
| +66% | +$13.2M |
|
|
CTLT
32
DELISTED
CATALENT, INC.
CTLT
| $35.1M | 1.14% |
337,000
+18,900
| +6% | +$1.83M |
|
33
Vertex Pharmaceuticals
VRTX
$124B
| $34.8M | 1.13% |
+147,300
| New | +$33.8M |
|
34
Anika Therapeutics
ANIK
$202M
| $33.1M | 1.07% |
731,000
+129,300
| +21% | +$4.91M |
|
|
SGTX
35
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $33M | 1.07% |
+52,923
| New | +$24M |
|
|
EXAS
36
DELISTED
Exact Sciences
EXAS
| $32.7M | 1.06% |
+247,000
| New | +$29.9M |
|
|
EPIX
37
DELISTED
ESSA Pharma
EPIX
| $30.5M | 0.99% |
2,558,000
+470,200
| +23% | +$3.31M |
|
38
Cardiff Oncology
CRDF
$63.6M
| $28.9M | 0.94% |
+1,607,000
| New | +$28.2M |
|
39
Neurocrine Biosciences
NBIX
$18.4B
| $28.8M | 0.93% |
+300,000
| New | +$29M |
|
40
Acadia Pharmaceuticals
ACAD
$4.45B
| $28.2M | 0.92% |
+527,600
| New | +$26.2M |
|
41
Aurinia Pharmaceuticals
AUPH
$1.92B
| $27.7M | 0.9% |
2,000,000
-1,564,900
| -44% | -$22.8M |
|
42
Zymeworks
ZYME
$1.66B
| $27.3M | 0.89% |
578,100
+333,400
| +136% | +$15.5M |
|
|
BPMC
43
DELISTED
Blueprint Medicines
BPMC
| $26.9M | 0.87% |
+240,000
| New | +$25.3M |
|
44
Alphatec Holdings
ATEC
$1.43B
| $26.9M | 0.87% |
+1,850,873
| New | +$19.5M |
|
45
BioXcel Therapeutics
BTAI
$26.1M
| $25.3M | 0.82% |
34,188
+563
| +2% | +$439K |
|
46
AtriCure
ATRC
$2.01B
| $24.9M | 0.81% |
+446,600
| New | +$19.3M |
|
47
Collegium Pharmaceutical
COLL
$1.16B
| $24.8M | 0.81% |
1,239,000
+238,600
| +24% | +$4.66M |
|
48
Sotera Health
SHC
$5.06B
| $19.2M | 0.62% |
+700,000
| New | +$18.8M |
|
49
Curis
CRIS
$9.41M
| $19.2M | 0.62% |
+5,855
| New | +$7.03M |
|
50
SI-BONE Inc
SIBN
$795M
| $19.1M | 0.62% |
+639,884
| New | +$15.6M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q4 2020 Portfolio in Review
As of Q4 2020, Avidity Partners Management held 121 positions worth $3.08B, up 43% from $2.16B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Avidity Partners Management deployed $456M of net new capital in Q4 2020, opening 53 new positions and adding to 26 existing holdings. Its largest new stake was AstraZeneca: 1,150,000 shares worth $115M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 80% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $67.1M trimmed.
- Avidity Partners Management's largest Q4 2020 buy was AstraZeneca: 1,150,000 shares worth $115M.
- Avidity Partners Management added most to Avantor in Q4 2020, an estimated $51.7M increase.
- Avidity Partners Management's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $67.1M.
- Avidity Partners Management fully exited Seagen Inc. Common Stock in Q4 2020, selling an estimated $104M.
- Avidity Partners Management's ten largest holdings make up 38% of its $3.08B portfolio in Q4 2020.
- Avidity Partners Management opened 53 new positions and closed 25 in Q4 2020.
- Avidity Partners Management's portfolio value rose 43% quarter-over-quarter to $3.08B.
Based on Avidity Partners Management's 13F filing for Q4 2020, filed 16 Feb 2021.